Abstract
Multidrug resistance (MDR) in cancer cells can significantly attenuate the response to chemotherapy and increase the likelihood of mortality. The major mechanism involved in conferring MDR is the overexpression of ATP-binding cassette (ABC) transporters, which can increase efflux of drugs from cancer cells, thereby decreasing intracellular drug concentration. Modulators of ABC transporters have the potential to augment the efficacy of anticancer drugs. This editorial highlights some major findings related to ABC transporters and current strategies to overcome MDR.
Publication types
-
Editorial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters / antagonists & inhibitors
-
ATP-Binding Cassette Transporters / metabolism*
-
Antineoplastic Agents / therapeutic use
-
Drug Resistance, Multiple
-
Drug Resistance, Neoplasm*
-
Humans
-
Molecular Targeted Therapy
-
Multidrug Resistance-Associated Proteins / antagonists & inhibitors
-
Multidrug Resistance-Associated Proteins / metabolism
-
Nanomedicine*
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / metabolism
-
Neoplasms / drug therapy*
-
Neoplasms / metabolism
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
Substances
-
ABCG2 protein, human
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters
-
Antineoplastic Agents
-
Multidrug Resistance-Associated Proteins
-
Neoplasm Proteins
-
Protein-Tyrosine Kinases
-
multidrug resistance-associated protein 1